The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
A phase II, open-label pilot study evaluating the safety and activity of Nal-IRI in combination with 5-FU and oxaliplatin in preoperative treatment of pancreatic adenocarcinoma (NEO-Nal-IRI Study) (NCT03483038).
 
Hiral D. Parekh
No Relationships to Disclose
 
Jessica L. Cioffi
No Relationships to Disclose
 
Kathryn Hitchcock
No Relationships to Disclose
 
Ji-Hyun Lee
No Relationships to Disclose
 
Z. Hugh Fan
No Relationships to Disclose
 
Carmen Joseph Allegra
No Relationships to Disclose
 
Steven J. Hughes
No Relationships to Disclose
 
Jose Gilberto Trevino
No Relationships to Disclose
 
David L. DeRemer
Honoraria - Bristol-Myers Squibb (I); Bristol-Myers Squibb (I); Bristol-Myers Squibb (I); Bristol-Myers Squibb (I); Pfizer (I); Pfizer (I); Pfizer (I); Pfizer (I)
Consulting or Advisory Role - Amgen; Amgen; Amgen; Amgen
Speakers' Bureau - Bristol-Myers Squibb (I); Bristol-Myers Squibb (I); Bristol-Myers Squibb (I); Bristol-Myers Squibb (I); Pfizer (I); Pfizer (I); Pfizer (I); Pfizer (I)
 
Thomas J. George
Consulting or Advisory Role - Bayer/Onyx; Bayer/Onyx; Bayer/Onyx; Bayer/Onyx; Merck; Merck; Merck; Merck
Research Funding - AstraZeneca/MedImmune (Inst); AstraZeneca/MedImmune (Inst); AstraZeneca/MedImmune (Inst); AstraZeneca/MedImmune (Inst); Bayer (Inst); Bayer (Inst); Bayer (Inst); Bayer (Inst); Bayer/Onyx (Inst); Bayer/Onyx (Inst); Bayer/Onyx (Inst); Bayer/Onyx (Inst); Bristol-Myers Squibb (Inst); Bristol-Myers Squibb (Inst); Bristol-Myers Squibb (Inst); Bristol-Myers Squibb (Inst); Incyte (Inst); Incyte (Inst); Incyte (Inst); Incyte (Inst); Ipsen (Inst); Ipsen (Inst); Ipsen (Inst); Ipsen (Inst); Lilly (Inst); Lilly (Inst); Lilly (Inst); Lilly (Inst); Merck (Inst); Merck (Inst); Merck (Inst); Merck (Inst); Newlink Genetics (Inst); Newlink Genetics (Inst); Newlink Genetics (Inst); Newlink Genetics (Inst); Pharmacyclics (Inst); Pharmacyclics (Inst); Pharmacyclics (Inst); Pharmacyclics (Inst); Seagen (Inst); Seagen (Inst); Seagen (Inst); Seagen (Inst); Tesaro (Inst); Tesaro (Inst); Tesaro (Inst); Tesaro (Inst)